Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function

British Journal of Anaesthesia

Volumn 101, Issue 4, 2008, Pages 492-497

  Staals, L M ^a   Snoeck, M M J ^b   Driessen, J J ^a   Flockton, E A ^c   Heeringa, M ^d   Hunter, J M ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c School of Anaesthesia   (United Kingdom)

^d NV ORGANON   (Netherlands)

Author keywords

Complications, renal; Kidney, failure; Neuromuscular block, antagonism; Neuromuscular block, rocuronium; Safety, drug

Indexed keywords

OPIATE; PROPOFOL; ROCURONIUM; SUGAMMADEX;

ADULT; AGED; ANESTHESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 51849115179     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen216     Document Type: Article

References (25)

1. Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332: 1691-9
2. Caldwell JE. Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth Analg 1995; 80: 1168-74
3. Berg H, Roed J, Viby-Mogenson J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095-103
4. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS, Jensen EW. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Can J Anaesth 1996; 43: 932-8
5. Reid JE, Breslin DS, Mirakhur RK, Hayes AH. Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol. Can J Anaesth 2001; 48: 351-5
6. van den Broek L, Proost JH, Wierda JM. Early and late reversibility of rocuronium bromide. Eur J Anaesthesiol 1994; 9: 128-32
7. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed 2002; 41: 265-70
8. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex; a dose-finding and safety study. Anesthesiology 2006; 104: 667-74
9. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetics. Br J Anaesth 2006; 97: 123-6
10. Robertson EN, Driessen JJ, Booij LHDJ. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. Eur J Anaesthesiol 2005; 22: 4-10
11. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703
12. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
13. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogenson J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808
14. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003; 98: 1037-9
15. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block ( part II). Br J Anaesth 1971; 43: 478-85
16. International Conference on Harmonization. Guideline for Good Clinical Practice. 1997
17. Bom AH, Van Egmond J, Hope F, Van de Pol F. Rapid reversal of rocuronium-induced neuromuscular block by Org 25969 is independent of renal perfusion. Anesthesiology 2003; 99: A1158
18. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104: 575-81
19. McCourt KC, Mirakhur RK, Kerr CM. Dosage of neostigmine for reversal of rocuronium block from two levels of spontaneous recovery. Anaesthesia 1999; 54: 651-5
20. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104: 569-74
21. Capron F, Alla F, Hottier C, Meistelman C, Fuchs-Buder T. Can acceleromyography detect low levels of residual paralysis? A probability approach to detect a mechanomyographic train-of-four ratio of 0.9. Anesthesiology 2004; 100: 1119-24
22. Samet A, Capron F, Alla F, Meistelman C, Fuchs-Buder T. Single acceleromyography train-of-four: 100-hertz tetanus or double-burst stimulation: which test performs better to detect residual paralysis? Anesthesiology 2005; 102: 51-6
23. Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (ORG 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71: 222-6
24. Cooper RA, Mirakhur RK, Wierda JMKH, Maddineni VR. Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Eur J Anaesthesiol 1995; 11: 43-4
25. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology 2007; 106: 935-43